Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cannabidiol and Management of Endometriosis Pain
NCT04527003 · Milton S. Hershey Medical Center · PHASE3 · terminated · last registry update 2025-04-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment has been challenging due to the BMI cutoff, need to take oral progesterone and abstain from cannabis products prior to the study.” | – | Registry record, Milton S. Hershey Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-01Phase 3 first posted: University of Pennsylvania, 200mg mifepristone and 800mg misoprostol (NCT07506512)
- 2026-03-18Results posted on the registry: Washington University School of Medicine, Mifepristone + Misoprostol (NCT05322252)
- 2026-03-04Phase 3 first posted: University of Utah, Levonorgestrel 1.5 mg and Piroxicam 40 mg + Oral LNG + Placebo (NCT07449299)
- 2026-02-23Also stopped (withdrawn): University of Virginia, Metformin + Oral combined hormonal contraceptives (NCT03905941)
- 2026-02-09Results posted on the registry: Kimberly Myer, Nestorone + Testosterone Combination Gel (NCT02994602)
- 2026-01-23Results posted on the registry: Premier Research, 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR) (NCT00455156)
- 2026-01-12Also stopped (withdrawn): Washington University School of Medicine, Semaglutide + Placebo (NCT05829460)
- 2026-01-07Results posted on the registry: Premier Research, levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2 + levonorgestrel patch with BMI <32 kg/m2 (NCT01166412)
- 2025-12-23Also stopped (terminated): University of Chicago, Pembrolizumab + Mifepristone (NCT03225547)
- 2025-12-08Results posted on the registry: Kimberly Myer, 10 µg/day E2 with NES 200® µg/day + 20 µg/day E2 with NES 200® µg/day (NCT01586000)
- 2025-11-21Results posted on the registry: Organon and Co, NOMAC-E2 COC (NCT05264506)
- 2025-11-21Also stopped (terminated): Organon and Co, NOMAC-E2 COC (NCT05264506)
- 2025-11-20Also stopped (terminated): Kimberly Myer, Ulipristal Acetate + Levonorgestrel (NCT03537768)
- 2025-11-14Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Evobruitnib + Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)] (NCT07215806)
- 2025-08-28Also stopped (withdrawn): Endeavor Health, Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet (NCT06279195)
- 2025-08-26Results posted on the registry: GlaxoSmithKline, Microgynon + GSK3036656 (NCT06354257)
- 2025-08-05Also stopped (terminated): The University of Queensland, Danazol + Placebo (NCT04638517)
- 2025-08-03Phase 3 first posted: University of Michigan, Relugolix CT (NCT07100782)
- 2025-07-22Results posted on the registry: AbbVie, Elagolix + Estradiol /norethindrone acetate (E2/NETA) (NCT03271489)
- 2025-07-20Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, a drug against PGR (NCT01088178)
- 2025-07-20Also stopped (withdrawn): United States Naval Medical Center, Portsmouth, a drug against PGR (NCT01161095)
- 2025-06-06Also stopped (withdrawn): University of Chicago, a drug against PGR (NCT06456164)
- 2025-05-30Results posted on the registry: Johns Hopkins University, Mifepristone + Placebo - Cap (NCT02989662)
- 2025-05-30Results posted on the registry: University of Colorado, Denver, Desogestrel and Ethinyl Estradiol Tablets (NCT05002738)
- 2025-04-08Results posted on the registry: University of Alabama at Birmingham, Etonogestrel (ETG) implant + Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (NCT04669678)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision